Study Enrollment

Your details will not be published or shared.

Clinical Trial

(RWE Registry) Registry to Evaluate Effectiveness and Safety of the Nanoknife System for the Ablation of Stage 3 Pancreatic Adenocarcinoma

This is a registry study that will collect data from patients who are treated using the Nanoknife machine. It is being done to see if this machine that kills cells is safe and helpful in your type of pancreatic cancer. The information gathered from using this machine will be compared to the information from patients receiving only standard treatment.

Eligibility Criteria

  • Adults with stage 3 pancreatic cancer, cytologically or pathologically confirmed Patient has received three months of standard of care treatment according to the institution?s guidelines Patient shows no evidence of disease progression after completing three months of SOC

Contact Information

    Edward James Kruse, MD

    (706) 721-4726